HHS Releases COVID-19 Monoclonal Antibody to Treat Uninsured, Underinsured Patients

Health care providers who treat uninsured or underinsured patients with commercially procured bebtelovimab, a COVID-19 monoclonal antibody therapy for outpatients at high risk for hospitalization, may be eligible for free replacement doses from the U.S. Department of Health and Human Services. HHS plans to make 60,000 doses of the product available to providers under the initiative. Anticipating depletion of the federal government’s supply, HHS last month transitioned to commercial distribution of the therapy.

Through this new initiative, which is effective immediately, health care providers who use a commercially procured dose of bebtelovimab to treat an uninsured or underinsured patient may be eligible to have the dose replaced for free by HHS. Health care providers can use their own established methods for determining uninsured or underinsured status, such as eligibility criteria for existing programs for which a patient may already be eligible.